Loading clinical trials...
Loading clinical trials...
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Conditions
Interventions
INS018_055
Placebo
Locations
12
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
HonorHealth Research Institute
Scottsdale, Arizona, United States
Keck School of Medicine of USC
Los Angeles, California, United States
Florida Lung Asthma and Sleep Specialist
Celebration, Florida, United States
Central Florida Pulmonary Group, P.A. (CFPG) - Downtown Orlando
Orlando, Florida, United States
Southeastern Research Center
Winston-Salem, North Carolina, United States
Start Date
February 8, 2024
Primary Completion Date
February 28, 2026
Completion Date
February 28, 2026
Last Updated
November 12, 2025
NCT07466420
NCT07332117
NCT04598919
NCT06922916
NCT06650774
NCT05387785
Lead Sponsor
InSilico Medicine Hong Kong Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions